Chatterjee, S.Biondi, I.Dyson, P. J.Bhattacharyya, A.2011-06-072011-06-072011-06-07201110.1007/s00775-011-0772-0https://infoscience.epfl.ch/handle/20.500.14299/68488WOS:000290773500004The organometallic glutathione S-transferase inhibitor ruthenium(II) (ethacrynic acid-η6-benzylamide)(1,3,5-triaza-7-phosphaadamantane) dichloride, termed ethaRAPTA, has been demonstrated to induce apoptosis in the cisplatin-resistant MCF-7 breast cancer cell line. Probing the molecular basis of this activity suggests that the complex triggers multiple pathways toward apoptosis, including those involving endonuclease G, caspases, and c-Jun N-terminal kinase, which could provide a therapy for multi-drug-resistant tumors. Furthermore, the induction of heat shock protein 70 expression enhances selectivity of the complex for tumor cells, reducing the general toxicity. © 2011 SBIC.ChemotherapeuticsBioorganometallic chemistryMitochondriaRutheniumReactive oxygen speciesS-Transferase P1-1Anticancer DrugsIn-VitroPreclinical DevelopmentCarcinoma-CellsSerum-ProteinsBreast-CancerPhase-IGlutathioneComplexestext::journal::journal article::research article